Recent Updates
Recently added Catalysts
TLX Negative Sentiment

TELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th

Key Takeaway: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Telix Pharmaceuticals Limited for alleged misleading statements regarding its business operations. The lawsuit covers investors who acquired Telix securities between February 21, 2025, and August 28, 2025. It claims that the company overstated its progress in prostate cancer therapeutics and the quality of its supply chain. Investors are encouraged to apply to be lead plaintiffs before the deadline of January 9, 2026.
Price reaction · baseline $7.62 (2026-01-02 close) · 2 other TLX headline(s) in the window, move may be shared
day 0 close
-0.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Telix Pharmaceuticals for making misleading statements.
  • The lawsuit claims that Telix overstated the progress and quality of its prostate cancer therapeutic candidates and supply chain.
  • Investors may have suffered damages due to the alleged false claims about Telix’s business and prospects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Telix securities between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) in the United States District Court for the Southern District of Indiana on behalf of all persons and entities who purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”).
Investors have until January 9, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Frequently Asked Questions

Who should contact Bragar Eagel & Squire regarding Telix?

Investors who suffered losses in Telix securities between February 21 and August 28, 2025.

What is the deadline to apply as lead plaintiff in the lawsuit?

Investors have until January 9, 2026, to apply for lead plaintiff status.

What does the Telix lawsuit claim?

It claims defendants overstated progress on prostate cancer treatments and supply chain quality.

How can investors get more information about the claims?

Investors can contact Brandon Walker or Melissa Fortunato via email or phone.

Is there a cost to contact Bragar Eagel & Squire?

There is no cost or obligation to contact the firm regarding these matters.

Last updated: Jan 5, 2026